Home
/ Vivesto
/ Competitors

Vivesto Competitors and Similar CompaniesClear all

Vivesto's competitors and similar companies include Patterson Companies, Sirnaomics, Luzitin and Merck.

	Vivesto Vivesto (formerly known as Oasmia Pharmaceutical) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology.	Patterson Companies Patterson Companies is a medical supplies company operating in the business of veterinary and dental products.	Sirnaomics Sirnaomics is a biopharmaceutical company that specializes in drug development solutions.	Luzitin Luzitin is a pharmaceutical company that specializes in photodynamic therapy (PDT) and photodiagnosis (PDD).	Merck Merck (also known as MSD) is a company that develops and manufactures medicines and vaccines for human and animal health.
Founding Date	Founding Date 1990	Founding Date 1877	Founding Date 2007	Founding Date 2010	Founding Date 1891
Type	Type Public	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare distribution drug development oncology pharma therapy veterinary	Tags Healthcare dental distribution lifestyle pharma rehabilitation veterinary	Tags Healthcare drug development oncology pharma therapy	Tags Healthcare drug development oncology pharma therapy	Tags Healthcare biotech distribution drug development pharma veterinary
Locations	Locations Uppsala, SE HQ Solna, SE	Locations Mendota Heights, US HQ Denver, US Potomac, US Alachua, US Albuquerque, US Alexandria, US Amarillo, US see more	Locations Gaithersburg, US HQ Guangzhou, CN Suzhou, CN Hong Kong, HK Cambridge, US	Locations Coimbra, PT HQ	Locations Rahway, US HQ Munro, AR Macquarie Park, AU Krems An Der Donau, AT Wien, AT Bruxelles, BE Santa Cruz De La Sierra, BO see more
Employees	Employees 4	Employees 7,6001% decrease	Employees N/A	Employees 9	Employees 73,0004% increase
Valuation ($)	Valuation ($) 13.6 m	Valuation ($) 1.9 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 294.7 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $6.6b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $65b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $5.2b (FY, 2024)	Cost of goods N/A	Cost of goods N/A	Cost of goods $16.4b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $1.4b (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit $48.6b (FY, 2025)
Net income	Net income (kr34.1m) (FY, 2025)	Net income $185.5m (FY, 2024)	Net income N/A	Net income N/A	Net income $18.3b (FY, 2025)